Lynch & Associates IN Sells 1,385 Shares of Johnson & Johnson (NYSE:JNJ)

by · The Markets Daily

Lynch & Associates IN lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.5% during the 4th quarter, HoldingsChannel reports. The fund owned 89,415 shares of the company’s stock after selling 1,385 shares during the period. Johnson & Johnson accounts for approximately 2.8% of Lynch & Associates IN’s portfolio, making the stock its 9th biggest holding. Lynch & Associates IN’s holdings in Johnson & Johnson were worth $12,931,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Bright Futures Wealth Management LLC. boosted its position in Johnson & Johnson by 2.9% during the second quarter. Bright Futures Wealth Management LLC. now owns 3,389 shares of the company’s stock worth $495,000 after purchasing an additional 94 shares during the period. Sachetta LLC boosted its stake in Johnson & Johnson by 5.6% during the 2nd quarter. Sachetta LLC now owns 6,797 shares of the company’s stock valued at $1,097,000 after purchasing an additional 359 shares during the period. Andra AP fonden increased its position in Johnson & Johnson by 144.0% in the 2nd quarter. Andra AP fonden now owns 461,200 shares of the company’s stock worth $67,409,000 after buying an additional 272,200 shares during the period. Doheny Asset Management CA boosted its position in shares of Johnson & Johnson by 65.1% in the second quarter. Doheny Asset Management CA now owns 16,327 shares of the company’s stock valued at $2,296,000 after acquiring an additional 6,437 shares during the period. Finally, First Interstate Bank grew its stake in shares of Johnson & Johnson by 4.3% in the second quarter. First Interstate Bank now owns 9,260 shares of the company’s stock worth $1,353,000 after acquiring an additional 384 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $0.20 during trading hours on Friday, hitting $142.07. 8,646,981 shares of the company’s stock traded hands, compared to its average volume of 8,004,223. The company has a fifty day simple moving average of $150.03 and a 200-day simple moving average of $156.04. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The stock has a market capitalization of $342.05 billion, a price-to-earnings ratio of 20.56, a PEG ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.66 EPS. Equities research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.49%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Guggenheim raised their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Finally, Wells Fargo & Company boosted their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.71.

View Our Latest Analysis on JNJ

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).